Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 12Gliosarcoma 9Central Nervous System Neoplasms 6Astrocytoma 6Brain Neoplasms 5Oligodendroglioma 4Glioma 4Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 2Ovarian Neoplasms 2Glioma, Subependymal 2Ependymoma 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sinonasal Squamous Cell Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Pinealoma 1Pheochromocytoma 1Peritoneal Neoplasms 1Pancreatic Intraductal Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Mesothelioma 1Meningioma 1Melanoma 1

Interventions

Erlotinib Hydrochloride 2dehydroftorafur 1X-Rays 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Immunohistochemistry 1Gemcitabine 1Fluorouracil 1Drug Therapy 1Congresses as Topic 1Capecitabine 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pancreatic Intraductal Neoplasms × Surgical Procedures, Operative × Clear all
NCT00482625 2014-10-16

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 8 charts
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡